Coherus BioSciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2012
Net Income	-59.29	-237.89	-291.75	-287.1	132.24	89.83	Upgrade
Depreciation & Amortization	6.83	6.27	6.2	5.66	2.89	5.05	Upgrade
Share-Based Compensation	38.15	43.11	50.74	51.36	38.16	33.59	Upgrade
Other Operating Activities	-138.6	13.63	-6.31	192.64	-19.15	-100.12	Upgrade
Operating Cash Flow	-152.92	-174.88	-241.12	-37.43	154.15	28.36	Upgrade
Operating Cash Flow Growth	-	-	-	-	443.63%	-	Upgrade
Capital Expenditures	0.53	0.56	-2.04	-1.29	-7.06	-1.82	Upgrade
Acquisitions	194.82	7	-35	-136	-7.5	-11.08	Upgrade
Change in Investments	135.52	138.14	-127.38	-1.12	0.16	0.17	Upgrade
Other Investing Activities	-1	-1.05	-2.43	-	-	-	Upgrade
Investing Cash Flow	329.88	144.64	-166.85	-138.41	-14.4	-12.73	Upgrade
Share Issuance / Repurchase	69.08	74.22	9.37	54.3	21.23	17.23	Upgrade
Debt Issued / Paid	0	0	49.93	0	203.99	72.96	Upgrade
Other Financing Activities	-2.4	-4.62	-4.97	-2.43	-1.27	-0.82	Upgrade
Financing Cash Flow	66.68	69.6	54.33	51.88	223.95	89.37	Upgrade
Exchange Rate Effect	0	0	0	0	0	-0.28	Upgrade
Net Cash Flow	243.64	39.36	-353.65	-123.96	363.69	104.72	Upgrade
Free Cash Flow	-152.39	-174.33	-243.16	-38.72	147.09	26.53	Upgrade
Free Cash Flow Growth	-	-	-	-	454.36%	-	Upgrade
Free Cash Flow Margin	-50.48%	-67.77%	-115.22%	-11.86%	30.91%	7.45%	Upgrade
Free Cash Flow Per Share	-1.35	-1.85	-3.13	-0.51	2.06	0.38	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).